Q3 2017 Allergan plc Earnings Conference Call (Live)
11/01/17 at 8:30 a.m. ET
Allergan Issues Investor FAQ on Federal District Court RESTASIS® Patent Decision
U.S. District Court for the Eastern District of Texas Issues Adverse Trial Decision Concerning RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patents
Allergan to Present New Data at the World Congress of Gastroenterology at ACG 2017
Allergan Announces Settlement on RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patent Litigation with InnoPharma, Inc.
Allergan to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical Dermatology Conference